Chalfont St. Giles, UK, 2 May 2017 – Broadening its range of diagnostic options for clinicians and their patients, GE Healthcare announced today that it has received an indication approval from the U.S. Food and Drug Administration (FDA) for its imaging agent Visipaque™ (iodixanol) Injection. Visipaque 320 mg Iodine/mL is an iso-osmolar agent that is... Read more
EDEN PRAIRIE, MN, April 24, 2017 /PRNewswire/ — MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test systems and sensors, has strengthened its global reputation as the industry leader in materials and structures testing for mission critical purposes. Through application of its comprehensive materials test technology, MTS is playing an integral part in... Read more
Thermo Fisher Scientific has signed an agreement with the Institute of Medical Genetics and Pathology at University Hospital Basel, Switzerland, to establish the leading institution as the first partner in the Next Generation Sequencing Companion Dx Center of Excellence Program, a new initiative designed to develop and refine Thermo Fisher’s NGS-based research assays from its... Read more
April 19, 2017 12:07 PM Pacific Daylight Time MADISON, Wis.–(BUSINESS WIRE)–Cellular Dynamics International (CDI), a FUJIFILM company and a leading developer and manufacturer of induced pluripotent stem cells (iPS), today announced it has signed a collaboration agreement with the Harvard Stem Cell Institute (HSCI), a novel network of stem cell scientists that extends from the... Read more
Award Supports International Collaboration on Two-Dimensional Liquid Chromatography SANTA CLARA, Calif., April 19, 2017 Agilent Technologies Inc. (NYSE: A) announced today that Prof. Dwight Stoll has received an Agilent Thought Leader Award in support of his research applying two-dimensional liquid chromatography (2D-LC) to biopharmaceutical analysis. An influential researcher in chromatography, Prof. Stoll specializes in multi-dimensional... Read more
Basel, 19 April 2017 Roche to present new data at AAN reinforcing efficacy and safety of newly FDA-approved OCREVUS™ (ocrelizumab) in two types of multiple sclerosis Data presentations will include platform sessions and posters across relapsing multiple sclerosis and primary progressive multiple sclerosis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data on... Read more
Basel, 18 April 2017 FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more
Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more
Basel, 18 April 2017 FDA approves Roche’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States First and only medicine approved to treat all forms of diabetic retinopathy Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of... Read more